Arbutus Biopharma Inc (NASDAQ:ABUS – Get Rating) will release earnings data ahead of market open Thursday, May 5. Analysts expect Arbutus Biopharma to post earnings of ($0.13) per share for the quarter. Those interested in participating in the company’s earnings conference call can do so using this link.
Arbutus Biopharma (NASDAQ:ABUS – Get Rating) last announced its quarterly results on Thursday, March 3. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.16) by $0.01. The company posted revenue of $3.21 million in the quarter, versus a consensus estimate of $3.39 million. Arbutus Biopharma had a negative net margin of 693.91% and a negative return on equity of 676.58%. During the same quarter last year, the company posted ($0.23) EPS. On average, analysts expect Arbutus Biopharma to post EPS of -$1 for the current fiscal year and EPS of -$1 for the next fiscal year.
Shares of ABUS opened at $2.43 on Thursday. The company has a 50-day simple moving average of $2.91 and a 200-day simple moving average of $3.34. The company has a market capitalization of $361.41 million, a PE ratio of -2.93 and a beta of 2.67. Arbutus Biopharma has a 52 week minimum of $2.38 and a 52 week maximum of $6.50.
Institutional investors have recently increased or reduced their stake in the company. Bank of New York Mellon Corp increased its stake in Arbutus Biopharma shares by 7.1% during the third quarter. Bank of New York Mellon Corp now owns 256,921 shares of the biopharmaceutical company worth $1,102,000 after buying 16,929 additional shares in the last quarter. Cubist Systematic Strategies LLC increased its equity stake in Arbutus Biopharma by 1,838.1% during the 4th quarter. Cubist Systematic Strategies LLC now owns 263,588 shares of the biopharmaceutical company worth $1,025,000 after purchasing an additional 249,988 shares last quarter. Royal Bank of Canada increased its stake in Arbutus Biopharma shares by 145.2% during the third quarter. Royal Bank of Canada now owns 144,437 shares of the biopharmaceutical company worth $620,000 after buying an additional 85,542 shares in the last quarter. JPMorgan Chase & Co. increased its position in Arbutus Biopharma shares by 13.6% in the fourth quarter. JPMorgan Chase & Co. now owns 42,737 shares of the biopharmaceutical company worth $166,000 after acquiring 5,126 additional shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new equity stake in Arbutus Biopharma in the fourth quarter worth approximately $156,000. 54.40% of the shares are currently held by institutional investors.
A number of brokerages have recently released reports on ABUS. Jefferies Financial Group upgraded shares of Arbutus Biopharma from a “hold” rating to a “buy” rating and raised its price target for the company from $4.00 to $5.00 in a Wednesday report 2 february. StockNews.com took over coverage of Arbutus Biopharma shares in a Thursday, March 31 report. They set a “holding” rating for the company. Chardan Capital raised its price target on Arbutus Biopharma shares from $5.50 to $6.00 and gave the company a “buy” rating in a Friday, March 4 report. HC Wainwright raised its price target on Arbutus Biopharma shares from $8.00 to $8.50 and gave the company a “buy” rating in a Monday, March 14 report. Finally, Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a Thursday, March 10 report. Two research analysts gave the stock a hold rating and four gave the company a buy rating. Based on data from MarketBeat.com, the stock currently has an average buy rating and an average price target of $6.50.
About Arbutus Biopharma (Get a rating)
Arbutus Biopharma Corporation, a biopharmaceutical company, is developing novel therapies for chronic hepatitis B virus (HBV), SARS-CoV-2, and other coronavirus infection in the United States. Its HBV product portfolio consists of AB-729, a proprietary RNA interference product candidate administered subcutaneously, which in a Phase Ia/Ib clinical trial targeted hepatocytes, inhibiting viral replication and reducing various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
Get news and reviews for Arbutus Biopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Arbutus Biopharma and related companies with MarketBeat.com’s FREE daily email newsletter.